Skip to main content
GNLX logo

Genelux Corporation

GNLXNASDAQHealthcareBiotechnology

$2.48Today:- (-)1Y −53.73%

As of Oct 15, 2026 close

Market cap
$111.50M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$2.29$8.54
Volume (live)
-
Avg. volume (3M)
271.83K

Genelux (GNLX) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Genelux used $25.27M of cash in operating activities and spent $1.10M on capital expenditures. That left free cash flow of −$26.37M.

Genelux Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Genelux Corporation (GNLX) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2023FY 2022FY 2021FY 2020FY 2019
Period endingDec 2025Dec 2024Mar 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Operating Activities
Net Income-32.15-29.87-28.30-28.30-5.21-16.38-13.64-11.63
Depreciation & Amortization0.240.241.020.500.970.900.660.48
Deferred Income Tax0.000.000.00-0.000.350.000.00
Stock Based Compensation7.588.115.206.142.424.275.330.00
Change in Working Capital-1.050.75-3.28-3.28-1.694.080.380.08
Change in Accounts Payable-1.212.16-2.36-2.360.000.75-0.130.00
Change in Other Working Capital-0.27-0.29-0.92-0.04-1.693.330.510.08
Other Operating Activities0.10-0.465.084.66-0.060.200.073.85
Net Cash from Operating Activities-25.27-21.23-20.28-20.28-3.57-6.59-7.21-7.22
Investing Activities
Capital Expenditures-1.10-0.38-1.03-1.03-0.050.00-0.02-1.77
Purchases of Investments-18.26-29.00-13.70-13.700.000.000.000.00
Sales/Maturities of Investments31.5021.250.00-0.000.000.000.00
Net Cash from Investing Activities12.14-8.13-14.72-14.72-0.050.00-0.02-1.77
Financing Activities
Debt Repayment0.000.000.22-0.690.97-0.569.161.51
Common Stock Issued9.9028.5139.6544.110.120.148.996.38
Other Financing Activities0.000.694.16-0.30-1.570.150.000.00
Net Cash from Financing Activities9.9028.5144.0244.02-0.48-0.2718.157.89
Summary
Net Change in Cash-3.23-0.859.029.02-4.10-6.8610.93-1.11
Cash at Beginning of Period8.579.420.400.404.5011.350.431.53
Cash at End of Period5.338.579.429.420.404.5011.350.43
Free Cash Flow-26.37-21.61-21.30-21.30-3.62-6.59-7.23-8.99
Supplemental Disclosures
Interest Paid---0.070.260.910.68-

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Genelux Cash Flow

What is Genelux's free cash flow?

Genelux had negative free cash flow of $26.37M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$25.27M minus $1.10M of capital expenditures.

How much does Genelux spend on capital expenditures?

Genelux spent $1.10M on capital expenditures in fiscal 2025, compared with $381.00K a year earlier.

Does Genelux pay dividends or buy back shares?

Genelux's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition